4 research outputs found
Predicted Group Trajectories in Early Rheumatoid Arthritis based on DAS28 with 95% CI (n = 1,586).
<p>Five predicted group trajectories (solid or dashed lines) and 95% confidence interval limits (shaded) are depicted from the group-based trajectory modelling. Percentages reflect the predicted proportion of subjects in each group, which differs marginally from the actual group characterization in the dataset.</p
Inception characteristics of subjects in CATCH and of patients with available serial radiographs.
<p>* No significant differences identified except for anti-CCP (p<0.001); Swollen Joint Count (p<0.001), non-biologic DMARD combination therapy (p<0.01) and Steroid exposure (p = 0.003).</p><p>** Comorbidities recorded include: angina/heart attack, asthma, other heart problems, hypertension, cerebrovascular disease/accidents, anemia, bronchitis/emphysema, hypercholesterolemia, bowel disease, stomach ulcer, liver disease, kidney disease, tuberculosis, cancer, psoriasis, thyroid disease, diabetes, hepatitis, chronic infection, osteoarthritis, lupus, osteoporosis, back/spine problems, fibromyalgia, fractures, depression, mental illness, alcoholism, severe allergies, thromboembolic disease, Parkinson disease, migraines, seizures/epilepsy, gynecologic/prostate problems, HIV, herpes and/or cold sores.</p><p>*** Reported by site investigator; not from central reader</p><p>Results are reported as a Mean (SD) unless otherwise noted. RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; DAS28, disease activity score using a 28-joint count; HAQ Health Assessment Questionnaire; DMARD, disease modifying anti-rheumatic drug</p
Treatment by Trajectory Group.
<p>(A) Group Proportion on Methotrexate (≥15 mg), by Visit Month. (B) Group Proportion on Combination Methotrexate and DMARD Therapy, by Visit Month. (C) Group Proportion on Biologics, by Visit Month. (D) Group Proportion on Corticosteroids, by Visit Month.</p